Maruho Selects LifeSphere Safety and NavaX AI for Global Pharmacovigilance

Integrated LifeSphere Safety and NavaX AI capabilities will unify global safety operations, connect safety data, and accelerate AI-powered automation across Maruho's pharmacovigilance organization

Boston, Massachusetts - November 5, 2026 - ArisGlobal, an AI-first technology company at the forefront of life sciences and creator of LifeSphere®, today announced that Maruho Co., Ltd. has selected the LifeSphere® Safety and NavaX AI platforms as the technology foundation for its global pharmacovigilance strategy.

The implementation includes the following LifeSphere and NavaX capabilities:

• MultiVigilance - to modernize and unify global safety operations through a single safety database.

• NavaX Dynamic Data Extraction - to use GenAI to automatically extract structured safety data from source documents, including Japanese-language content with more than 95% data extraction accuracy.

• Business Intelligence - to provide greater visibility into safety operations through list outputs of safety information stored in LifeSphere MultiVigilance.

• Reporter - to simplify the collection of safety information from the field through secure web and mobile applications, supporting safety reporting activities.

• Literature Intelligence - to support the monitoring and management of safety information from global and local literature, including Japanese-language sources

The implementation will include the migration of existing safety records.

Following a comprehensive evaluation of multiple solutions, Maruho selected ArisGlobal based on an overall assessment of its proposed functionality, experience in Japan, implementation support, and alignment with Maruho's global pharmacovigilance objectives.

"Our objective is to establish a globally connected pharmacovigilance framework supported by consistent safety data management," said Hayato Yanagihara, PhD, Safety Control Manager and General Manager, Pharmacovigilance & PMS Department, Maruho Co., Ltd. "We selected ArisGlobal following a comprehensive evaluation of multiple solutions, including their ability to support our global safety operations and future organizational development."

"Across Japan, we're seeing life sciences organizations take a more strategic approach to pharmacovigilance by investing in platforms that can scale with their business and adapt to changing regulatory and operational demands," said Ken Kubota, Country Manager, Japan, ArisGlobal. "We're delighted to support Maruho on this journey and look forward to helping them realize the full value of their investment for years to come."

About Maruho

Maruho Co., Ltd. has its head office in Osaka and is one of Japan's leaders in research and development, manufacturing and commercialization of dermatological products. Founded in 1915, Maruho has 1,632 employees (as of the end of September 2025), and net sales were approximately 78.92 billion yen in its fiscal year ended September 30, 2025. With the mission "More smiles, brighter life for you.", Maruho aims to help realize a society where everyone can live with a smile. For more information, please visit

https://www.maruho.co.jp/english/

About ArisGlobal
ArisGlobal, an innovative life sciences technology company and creator of LifeSphere®, is transforming how today's most successful life sciences companies develop breakthroughs and bring new products to market. Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan, and China. For more updates, follow ArisGlobal on LinkedIn. www.arisglobal.com.